600613.SS SHH
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
1W: -13.2%
1M: -26.6%
3M: +74.3%
YTD: +25.8%
1Y: +17.5%
3Y: +27.2%
5Y: +67.1%
¥8.19 ($1.22)
+0.08 (+0.99%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$2.0B
-12.5% ▼
5Y CAGR: +1.2%
Gross Profit
$974M
-16.6% ▼
5Y CAGR: -4.4%
Operating Income
$92M
+10.7% ▲
5Y CAGR: -14.2%
Net Income
$71M
+25.2% ▲
5Y CAGR: -3.2%
EPS (Diluted)
$0.13
+18.2% ▲
5Y CAGR: -4.1%
EBITDA
$171M
-11.2% ▼
5Y CAGR: -0.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.3B | $2.4B | $2.3B | $2.0B |
| YoY Growth | -5.6% | +26.6% | +3.7% | -2.0% | -12.5% |
| Cost of Revenue | $735M | $917M | $1.1B | $1.2B | $1.1B |
| Gross Profit | $1.1B | $1.4B | $1.3B | $1.2B | $974M |
| Gross Margin | 59.6% | 60.2% | 52.9% | 49.9% | 47.5% |
| R&D Expenses | $43M | $51M | $46M | $32M | $33M |
| SG&A Expenses | $952M | $1.2B | $1.0B | $854M | $568M |
| Operating Expenses | $1.1B | $1.3B | $1.2B | $1.1B | $882M |
| Operating Income | $9M | $101M | $105M | $83M | $92M |
| Operating Margin | 0.5% | 4.4% | 4.4% | 3.5% | 4.5% |
| Interest Expense | $7M | $9M | $19M | $16M | $14M |
| Income Before Tax | -$340M | $100M | $63M | $83M | $88M |
| Tax Expense | $13M | $32M | $15M | $25M | $21M |
| Net Income | -$353M | $70M | $49M | $57M | $71M |
| Net Margin | -19.4% | 3.0% | 2.0% | 2.4% | 3.5% |
| EPS (Diluted) | $-0.66 | $0.13 | $0.09 | $0.11 | $0.13 |
| EBITDA | -$283M | $177M | $177M | $193M | $171M |
| Shares Outstanding | 533M | 536M | 539M | 518M | 549M |